<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205163</url>
  </required_header>
  <id_info>
    <org_study_id>242HA101</org_study_id>
    <secondary_id>242HA101</secondary_id>
    <nct_id>NCT03205163</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioverativ Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioverativ Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to assess the safety and tolerability of a single intravenous (IV)
      administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia
      A.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to 156 days</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>Up to 156 days</time_frame>
    <description>Clinically significant laboratory abnormalities including hematology, clinical chemistry, urinalysis, coagulation, thrombosis markers, and development of inhibitors (neutralizing antibodies directed against FVIII) as determined via the Nijmegen-modified Bethesda Assay (an inhibitor test result greater than or equal to (&gt;=) 0.6 Bethesda units (BU)/milliliter (mL), confirmed on 2 separate samples drawn 2 to 4 weeks apart, was considered positive).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Recombinant FVIII (rFVIII)</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2) of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>Time required for the concentration of the drug to reach half of its original value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State (Vss) of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>The apparent volume of distribution at steady state. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity Time (AUC [0-Infinity]) of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>The average time at which the number of absorbed molecules reside in the body, after single-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery (IR) of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1 Percent (%) Above Baseline for FVIII Activity of rFVIII</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>Time required for the concentration of the drug to reach half of its original value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State (Vss) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>The apparent volume of distribution at steady state. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity Time (AUC [0-Infinity]) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>The average time at which the number of absorbed molecules reside in the body, after single-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery (IR) of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1 Percent Above Baseline for FVIII Activity of BIVV001</measure>
    <time_frame>up to 336 hours postdose</time_frame>
    <description>Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Low-Dose Cohort: Recombinant FVIII (rFVIII) and BIVV001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous (IV) low dose of recombinant coagulation factor VIII (rFVIII) followed by a washout period of at least 72-hour, then a single IV low dose of BIVV001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Cohort: rFVIII and BIVV001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV high dose of rFVIII, followed by a washout period of at least 96-hour, then a single IV high dose of BIVV001.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant FVIII (rFVIII) (Low Dose)</intervention_name>
    <description>Participants will receive a single IV low dose of rFVIII.</description>
    <arm_group_label>Low-Dose Cohort: Recombinant FVIII (rFVIII) and BIVV001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rFVIII (High Dose)</intervention_name>
    <description>Participants will receive a single IV high dose of rFVIII.</description>
    <arm_group_label>High-Dose Cohort: rFVIII and BIVV001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BIVV001 (Low Dose)</intervention_name>
    <description>Participants will receive single IV low dose of BIVV001.</description>
    <arm_group_label>Low-Dose Cohort: Recombinant FVIII (rFVIII) and BIVV001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BIVV001 (High Dose)</intervention_name>
    <description>Participants will receive single IV high dose of BIVV001.</description>
    <arm_group_label>High-Dose Cohort: rFVIII and BIVV001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability of the participant, or his legally authorized representative (e.g., parent or
             legal guardian) if applicable in accordance with local regulations, to understand the
             purpose and risks of the study and provide signed and dated informed consent/assent
             and authorization to use confidential health information in accordance with national
             and local participant privacy regulations

          -  Severe hemophilia A, defined as less than (&lt;) 1 international units per deciliter
             (IU/dL) (&lt;1 percent [%]) endogenous FVIII at screening as determined by the one-stage
             clotting assay from the central laboratory. If the initial screening result is greater
             than or equal to (&gt;=) 1%, then a repeat endogenous FVIII activity level will be
             performed using the using the one stage clotting assay from the central laboratory. If
             the repeated result is &lt; 1 IU/dL (&lt;1%), then the participant will meet this inclusion
             requirement

          -  Previous treatment for hemophilia A, defined as at least 150 documented prior exposure
             days to any recombinant and/or plasma-derived FVIII and/or cryoprecipitate products at
             Day 1. Fresh frozen plasma treatment must not be considered in the count for
             documented exposure days

          -  Platelet count &gt;=100,000 cells/ microliter (mcL) at screening (test performed by the
             central laboratory and reviewed prior to the Day 1 Recombinant FVIII (rFVIII) dose)

          -  A participant known to be human immunodeficiency virus (HIV) antibody positive, either
             previously documented or identified from screening assessments, must have the
             following results prior to Day 1 rFVIII dose: cluster of differentiation 4 (CD4)
             lymphocyte count greater than (&gt;) 200 cells/millimeter (mm)^3; viral load of &lt;400
             copies/mL

        Exclusion Criteria:

        Medical History:

          -  Any concurrent clinically significant major disease that, in the opinion of the
             Investigator, would make the participant unsuitable for enrollment

          -  Serious active bacterial or viral infection (other than chronic hepatitis or HIV)
             present within 30 days of screening

          -  Other known coagulation disorder(s) in addition to hemophilia A

          -  History of hypersensitivity or anaphylaxis associated with any FVIII product

          -  Known or suspected allergy to mice, hamsters, or any ingredient in recombinant FVIII

          -  History of a positive inhibitor test or clinical signs of decreased response to FVIII
             administrations. Family history of inhibitors will not exclude the participant

        Medications and Procedures:

        - Current enrollment or participation within 30 days prior to screening in any other
        investigational study

        Other:

          -  Inability to comply with study requirements as assessed by the Investigator

          -  Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make
             the participant unsuitable for enrollment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bioverativ Therapeutics Inc, Waltham, MA, USA</last_name>
    <phone>1-888-794-1415</phone>
    <email>clinicaltrials@bioverativ.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara-Shi</city>
        <state>Nara-Ken</state>
        <zip>634-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo-To</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ogikubo Hospital</name>
      <address>
        <city>Tokyo</city>
        <state>Tokyo-To</state>
        <zip>167-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

